| Type of Material: | Thesis |
| Title: | Design and Synthesis of Benzimidazole Derivatives as Anti Cancer Agents |
| Researcher: | Rawat, Sushama |
| Guide: | Ghate, Manjunath |
| Department: | Institute of Pharmacy |
| Publisher: | Nirma University, Ahmedabad |
| Place: | Ahmedabad |
| Year: | 2024 |
| Language: | English |
| Subject: | Anti Cancer Agents | Benzimidazole Derivatives | Clinical Pre Clinical and Health | Pharmacology and Pharmacy | Pharmacology and Toxicology | Pharmacy | Medical Sciences | Medical and Health Sciences |
| Dissertation/Thesis Note: | PhD; Institute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad; 2024 |
| Fulltext: | Shodhganga |
| 000 | 00000ntm a2200000ua 4500 | |
| 001 | 456583 | |
| 003 | IN-AhILN | |
| 005 | 2024-10-11 11:57:06 | |
| 008 | __ | 241011t2024||||ii#||||g|m||||||||||eng|| |
| 035 | __ | |a(IN-AhILN)th_456583 |
| 040 | __ | |aNIRU_382481|dIN-AhILN |
| 041 | __ | |aeng |
| 100 | __ | |aRawat, Sushama|eResearcher |
| 110 | __ | |aInstitute of Pharmacy|bNirma University, Ahmedabad|dAhmedabad|ein|0U-0146 |
| 245 | __ | |aDesign and Synthesis of Benzimidazole Derivatives as Anti Cancer Agents |
| 260 | __ | |aAhmedabad|bNirma University, Ahmedabad|c2024 |
| 300 | __ | |dDVD |
| 502 | __ | |cInstitute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad|d2024|bPhD |
| 518 | __ | |d2024|oDate of Award |
| 518 | __ | |oDate of Registration|d2014 |
| 520 | __ | |aEpidermal growth factor receptor (EGFR) is a member of the ErbB receptor tyrosine kinase receptor family and is highly expressed in solid tumours. It is one of the important targets in the development of the anticancer compound. Inhibiting EGFR is an important part of cancer treatment because it stops the growth and spread of tumour cells that express EGFR. Agents that target EGFR work well to treat many types of cancer, especially colorectal, head and neck, lung, liver, and breast cancers. In this study, the goal was to come up with some new benzimidazole compounds that can interact with the EGFR kinase enzyme, and evaluation of their biological activities in vitro was aimed. To get to the target compounds, 1-methyl-1H-benzimidazol-2-amine was made by cycloadding o-phenylenediamine with cyanogen bromide in the presence of an aqueous base like ammonium hydroxide. This was followed by N-methylation with methyl iodide in the presence of anhydrous potassium hydroxide in acetone. Benzimidazole urea derivatives |
| 650 | __ | |aPharmacy|2UGC |
| 650 | __ | |aMedical Sciences|2UGC |
| 650 | __ | |aMedical and Health Sciences|2AIU |
| 653 | __ | |aAnti Cancer Agents |
| 653 | __ | |aBenzimidazole Derivatives |
| 653 | __ | |aClinical Pre Clinical and Health |
| 653 | __ | |aPharmacology and Pharmacy |
| 653 | __ | |aPharmacology and Toxicology |
| 700 | __ | |eGuide|aGhate, Manjunath |
| 856 | __ | |uhttp://shodhganga.inflibnet.ac.in/handle/10603/544012|yShodhganga |
| 905 | __ | |afromsg |
User Feedback Comes Under This section.